Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Cash & Equivalents (2021 - 2025)

Kezar Life Sciences' Cash & Equivalents history spans 5 years, with the latest figure at $38.9 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 11.7% year-over-year to $38.9 million; the TTM value through Sep 2025 reached $38.9 million, up 11.7%, while the annual FY2024 figure was $41.7 million, 17.63% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $38.9 million at Kezar Life Sciences, up from $34.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $105.4 million in Q2 2022 and bottomed at $22.9 million in Q1 2021.
  • The 5-year median for Cash & Equivalents is $36.1 million (2023), against an average of $41.7 million.
  • The largest annual shift saw Cash & Equivalents surged 299.47% in 2022 before it plummeted 73.33% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $62.9 million in 2021, then crashed by 35.66% to $40.5 million in 2022, then fell by 12.27% to $35.5 million in 2023, then rose by 17.63% to $41.7 million in 2024, then fell by 6.74% to $38.9 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Cash & Equivalents are $38.9 million (Q3 2025), $34.4 million (Q2 2025), and $37.0 million (Q1 2025).